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Abstract. The aim of the present study was to evaluate the 
effect of bevacizumab on local tumor response and lung meta-
static potential during boron neutron capture therapy (BNCT) 
and in particular, the response of intratumor quiescent (Q) 
cells. B16-BL6 melanoma tumor-bearing C57BL/6 mice were 
continuously administered bromodeoxyuridine (BrdU) to 
label all proliferating (P) tumor cells. The tumors were irradi-
ated with thermal neutron beams following the administration 
of a 10B-carrier [L-para-boronophenylalanine-10B (BPA) or 
sodium mercaptoundecahydrododecaborate-10B (BSH)], 
with or without the administration of bevacizumab. This 
was further combined with an acute hypoxia-releasing agent 
(nicotinamide) or mild temperature hyperthermia (MTH, 
40˚C for 60 min). Immediately following the irradiation, 
cells from certain tumors were isolated and incubated with a 
cytokinesis blocker. The responses of the Q cells and the total 
(P+Q) cell populations were assessed based on the frequency 
of micronuclei using immunofluorescence staining for BrdU. 
In other tumor-bearing mice, 17 days following irradiation, 
lung metastases were enumerated. Three days following 
bevacizumab administration, the sensitivity of the total 
tumor cell population following BPA-BNCT had increased 
more than that following BSH-BNCT. The combination with 
MTH, but not with nicotinamide, further enhanced total 
tumor cell population sensitivity. Regardless of the presence 
of a 10B-carrier, MTH enhanced the sensitivity of the Q cell 
population. Regardless of irradiation, the administration of 
bevacizumab, as well as nicotinamide treatment, demonstrated 
certain potential in reducing the number of lung metastases 
especially in BPA-BNCT compared with BSH-BNCT. Thus, 
the current study revealed that BNCT combined with bevaci-
zumab has the potential to sensitize total tumor cells and cause 
a reduction in the number of lung metastases to a similar level 
as nicotinamide.
Introduction
The neutron capture reaction in boron [10B(n,α)7Li] is, in 
principle, very effective in destroying tumors, provided that 
a sufficient amount of 10B is accumulated in the target tumor 
and a sufficient number of very-low-energy thermal neutrons 
are delivered. The two particles generated in this reaction have 
a high linear energy transfer (LET) and have a range of ~1-2 
tumor cells in diameter. It is theoretically possible to destroy 
tumor cells without affecting adjacent healthy cells if 10B 
atoms are selectively accumulated in the interstitial space of 
tumor tissue and/or intracellular space of tumor cells. Thus, 
successful boron neutron capture therapy (BNCT) requires the 
selective delivery of large amounts of 10B to tumor cells (1).
The two most common 10B-carriers used in clinical BNCT 
trials, designed for the treatment of malignant gliomas, mela-
nomas, inoperable head and neck tumors, and oral cancer, 
are sodium mercaptoundecahydrododecaborate-10B (BSH, 
Na210B12H11SH) and L-para-boronophenylalanine-10B (BPA, 
C9H1210BNO4) (1). The delivery of 10B via BSH relies on 
passive diffusion from the blood to the brain tumor through a 
disrupted blood-brain barrier (2). Thus, the use of BSH results 
in a high concentration of boron in the blood and subsequent 
vascular damage during BNCT (3). BPA is designed to be 
taken up mainly by active transport across the cancer cell 
membrane (4). However, the transport mechanism is operative 
even in normal cells leading to the accumulation of BPA in 
normal brain tissues, although at a lower rate. Therefore, it 
has been suggested that tumor response may be improved by 
combining BSH and BPA (5).
Antiangiogenic therapy has been hypothesized to prevent 
vascular tumor growth and proliferation, thus depriving the 
tumor of the oxygen and nutrients necessary for survival (6). 
However, a subsequent study suggested that antiangiogenic 
therapy may also ‘normalize’ the tumor vasculature for a 
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short period of time, thereby providing a window of oppor-
tunity for improved drug delivery and enhanced sensitivity 
to radiation (6,7). Tumor hypoxia results from either limited 
oxygen diffusion (chronic hypoxia) or limited perfusion (acute 
hypoxia) (8). Previous studies have reported that acute and 
cyclic, but not chronic, hypoxia significantly increased the 
number of spontaneous lung metastases and that this effect 
was due to the influence of acute hypoxia treatment on the 
primary tumor (9,10).
In the present study, the efficiency of administering the 
vascular endothelial growth factor (VEGF) inhibitor, beva-
cizumab, in combination with BNCT, and further combined 
with the acute hypoxia-releasing agent, nicotinamide, or mild 
temperature hyperthermia (MTH) was evaluated. MTH has 
already demonstrated the potential to release tumor cells 
from diffusion-limited chronic hypoxia (11,12) in terms of 
local tumor response and lung metastasis. In addition, with 
regards to the local tumor response, the effect not only on the 
total tumor cell population [proliferating (P) + quiescent (Q)], 
but also on the Q cell population alone, was evaluated using 
an original method for selectively detecting the response of 
Q cells in solid tumors (13).
Materials and methods
Mice and tumors. B16-BL6 murine melanoma cells (Institute 
of Development, Aging and Cancer, Tohoku University, 
Sendai, Japan) derived from C57BL/6 mice were maintained 
in vitro in RPMI-1640 medium supplemented with 10% 
fetal bovine serum. Tumor cells (1.25x105) were inoculated 
subcutaneously into the left hind leg of 8-week-old syngeneic 
female C57BL/6 mice (Japan Animal Co., Ltd., Osaka, Japan). 
Eighteen days later, the tumors, ~7 mm in diameter, were 
employed for treatment. The body weight of the tumor-bearing 
mice was 20.1±2.3 g (mean ± standard error). The mice were 
handled according to the Recommendations for Handling of 
Laboratory Animals for Biomedical Research, compiled by 
the Committee on Safety Handling Regulations for Laboratory 
Animal Experiments at Tohoku University. The p53 of the 
B16-BL6 tumor cells was the wild-type (14).
Labeling with bromodeoxyuridine (BrdU). Twelve days 
following inoculation, mini-osmotic pumps (Durect 
Corporation, Cupertino, CA, USA) containing BrdU dissolved 
in physiological saline (250 mg/ml) were implanted subcu-
taneously into the backs of the animals for six days in order 
to label all P cells. The percentage of labeled cells following 
the continuous treatment with BrdU reached a plateau at this 
stage. Therefore, tumor cells not incorporating BrdU following 
continuous labeling were regarded as Q cells.
Treatment. Fifteen days following the tumor cell inocula-
tion, bevacizumab (a humanized monoclonal antibody 
against VEGF; Hoffmann-La Roche AG, Basel, Switzerland) 
dissolved in physiological saline was intravenously adminis-
tered through a tail vein, at a dose of 10 mg/kg in a single 
injection. Bevacizumab has previously been demonstrated to 
induce a period of vascular normalization in B16-F10 murine 
melanoma tumors originating from B16-F1 murine melanoma 
cells (15). Thus, in B16-BL6 tumors also originating from 
B16-F1 murine melanoma cells, it was hypothesized that beva-
cizumab would exhibit the same effect as in B16-F10 tumors. 
After three days (18 days following inoculation, on day 18), the 
percentages of labeled cells following the continuous admin-
istration of BrdU for six days were 60.1±6.8 and 54.3±6.1% 
for those treated with bevacizumab and those not, respectively.
BSH and BPA were purchased from KatChem Ltd. (Prague, 
Czech Republic), and prepared by dissolving in physiological 
saline for BSH (125 mg/kg) and as a complex with 3% fructose 
for BPA (250 mg/kg). They were injected intraperitoneally in 
a volume of 0.02 ml/g of mouse body weight. In accordance 
with previous studies (16), no overt toxicity was observed at 
a dose of <500 mg/kg for BSH and <1,500 mg/kg for BPA. 
Based on the certificate of analysis and material safety data 
sheet, provided by the manufacturer, borocaptate dimer 
(BSSB; 10B24H22S24-) was not present as a contaminant. The 
intratumor 10B concentration during neutron irradiation is a 
crucial determinant of the cell destruction effect of BNCT. In 
order to obtain similar intratumor 10B concentrations during 
exposure to the neutron beam, irradiation was initiated at 
selected time points following the intraperitoneal injec-
tion of the 10B-carriers at a selected dose of 10B. Based on a 
preliminary study of the biodistribution of 10B, irradiation was 
initiated from 60 min following intraperitoneal injection of 
125 and 250 mg/kg (71.0 and 12.0 mg 10B/kg) of BSH and 
BPA, respectively. 10B concentrations were determined using 
a thermal neutron guide tube installed at the Kyoto University 
Research Reactor (Osaka, Japan) (17).
Certain tumor-bearing mice also received an intraperito-
neal administration of nicotinamide (1,000 mg/kg) dissolved 
in physiological saline 1 h prior to neutron irradiation. Others 
were subjected to local MTH at 40˚C for 1 h by immersing 
the implanted tumor in a water bath prior to irradiation (18). 
Temperatures in the center of the tumors equilibrated within 
3-4 min following immersion in the water bath and remained 
at 0.2-0.3˚C below the temperature of the bath. The water 
temperature in the bath was maintained at 0.3˚C above the 
desired tumor temperature (18).
For irradiation of the tumors implanted into the left 
hind legs of the mice, a device composed of acrylic resin 
and capable of holding 12 mice was used. The tumor-
bearing mice were irradiated with a reactor neutron beam 
at a power of 1 MW at Kyoto University Research Reactor 
after being fixed in position with adhesive tape. A lithium 
fluoride (LiF) thermoplastic shield was employed to avoid 
irradiating body parts other than the implanted solid tumors. 
Neutron irradiation was performed using a reactor neutron 
beam with a cadmium ratio of 9.4. The neutron fluence was 
measured from the radioactivation of gold foil at both the 
front and back of the tumors. Since the tumors were small 
and located just beneath the skin surface, the neutron fluence 
was assumed to decrease linearly from the front to the back 
of the tumors. Thus, the average neutron fluence, determined 
from the values measured at the front and back of the tumor, 
was used. Contaminating γ-ray, including secondary γ-ray, 
doses were measured with a thermoluminescence dosimeter 
(TLD) powder placed at the back of the tumors. The TLD 
used was beryllium oxide (BeO) enclosed in a quartz glass 
capsule (Panasonic Corporation, Osaka, Japan). The BeO 
itself was not sensitive to thermal neutrons. The thermal 
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neutron fluence, of 8x1012/cm2, was equal to ~1 cGy γ-ray 
dose. TLD was normally used together with the gold activa-
tion foil for the neutron-sensitivity correction in the current 
study. The details were described in the study by Sakurai and 
Kobayashi (19). For the estimation of neutron energy spectra, 
eight types of activation foil and 14 types of nuclear reaction 
were used (19). The absorbed dose was calculated using the 
flux-to-dose conversion factor (20). The tumors contained H 
(10.7% in terms of weight), C (12.1%), N (2%), O (71.4%), and 
others (3.8%) (21). The average neutron flux and kerma rate 
of the employed beam were 1.0x109 n/cm/sec and 48.0 cGy/h 
for the thermal neutron range (<0.6 eV), 1.6x108 n/cm/sec 
and 4.6 cGy/h for the epithermal neutron range (0.6-10 keV), 
and 9.4x106 n/cm/sec and 32.0 cGy/h for the fast neutron 
range (>10 keV), respectively. The kerma rate for boron dose 
per φ n/cm/s of thermal neutron flux for 1 µg/g of 10B was 
2.67x10-8φ cGy/h. The contaminating γ-ray dose rate was 
66.0 cGy/h.
Each irradiation group also included mice that were not 
pre-treated with BrdU.
Immunofluorescence staining of BrdU-labeled cells and 
micronucleus (MN) assays. Immediately following irra-
diation, selected tumors were removed from the mice given 
BrdU. They were homogenized and trypsinized using 0.05% 
trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) in 
phosphate-buffered saline (PBS) at 37˚C for 15 min. Tumor 
cell suspensions were incubated for 72 h in tissue culture dishes 
containing complete medium and 1.0 µg/ml of cytochalasin B 
in order to inhibit cytokinesis while allowing nuclear division. 
The cultures were trypsinized and cell suspensions were fixed 
and resuspended with cold Carnoy's fixative (ethanol:acetic 
acid, 3:1 by volume). Each suspension was placed on a glass 
microscope slide, dried at room temperature and treated with 
2 M hydrochloric acid for 60 min at room temperature in order 
to dissociate the histones and partially denature the DNA. 
The slides were immersed in borax-borate buffer (pH 8.5) to 
neutralize the acid. BrdU-labeled tumor cells were detected 
by indirect immunofluorescence staining using a monoclonal 
anti-BrdU antibody (BD Biosciences, San Jose, CA, USA) and 
a fluorescein isothiocyanate (FITC)-conjugated antimouse 
IgG antibody (Sigma, St. Louis, MO, USA). To distinguish 
the tumor cells stained with green-emitting FITC and 
observe them separately, cells on the slides were treated with 
red-emitting propidium iodide (PI; 2 µg/ml in PBS) as a back-
ground stain and monitored under a fluorescence microscope 
(Olympus Bioimaging, Tokyo, Japan).
When cell division is disrupted, or the chromosomes are 
broken or damaged by chemicals or radiation, the distribution 
of genetic material between the two daughter nuclei during 
cell division is affected and pieces or entire chromosomes fail 
to be included in either of the two daughter nuclei. The genetic 
material that is not incorporated into a new nucleus forms a 
‘MN’. Thus, the frequency of MN formation accurately reflects 
the genotoxicity of a chemical compound and radiation. The 
MN frequency in cells not labeled with BrdU was examined 
by counting the micronuclei in the binuclear cells that showed 
only red fluorescence. The MN frequency was defined as the 
ratio of the number of micronuclei in the binuclear cells to the 
total number of binuclear cells observed (13).
The ratios obtained from the tumors not pretreated with 
BrdU indicated the MN frequencies at all phases in the total 
tumor cell population. More than 300 binuclear cells were 
counted to determine the MN frequency.
Clonogenic cell survival assay. Immediately following irra-
diation, a clonogenic cell survival assay was performed on the 
implanted tumors in mice that were not given BrdU using an 
in vivo-in vitro assay method. The BrdU-unlabeled tumors 
were removed, weighed, homogenized and disaggregated by 
stirring for 20 min at 37˚C in PBS containing 0.05 % trypsin 
and 0.02% EDTA. The cell yield was 1.2±0.4x107/g tumor 
weight. Appropriate numbers of viable tumor cells from the 
single cell suspension were plated on 60- or 100-mm tissue 
culture dishes and 12 days later, colonies were fixed with 
ethanol, stained with Giemsa and counted. For the tumors 
that received no irradiation, plating efficiencies for the total 
tumor cell populations and the MN frequencies for the total 
and Q cell populations are displayed in Table I. The plating 
efficiency indicates the percentage of cells seeded that grew 
into colonies when the tumors received no irradiation. The 
fraction of cells surviving a given dose was determined by 
counting the number of macroscopic colonies as a fraction of 
the total number of cells seeded, followed by allowance, that 
is, by dividing by the plating efficiency.
As stated above, the MN frequencies for Q cells were 
obtained from BrdU-unlabeled cells in tumors following contin-
uous BrdU labeling in vivo. The MN frequencies and surviving 
fractions (SFs) for the total tumor cell populations were obtained 
from cells in tumors not pretreated with BrdU. Thus, the present 
study was not able to detect any interaction between BrdU and 
irradiation in the data for the MN frequencies and SFs.
Metastasis assessment. Seventeen days following irradiation 
(35 days following the inoculation of B16-BL6 melanoma cells), 
the tumor-bearing mice were sacrificed by cervical dislocation. 
Their lungs were removed, briefly washed with distilled water, 
cleaned of extraneous tissue, fixed overnight in Bouin's solu-
tion (Sigma), and stored in buffered formalin 10% (Sigma) until 
metastases were counted. Macroscopically visible metastases 
were counted using a dissection microscope (22). Eighteen 
days following inoculation and immediately prior to exposure 
to the neutron beam, macroscopic lung metastases were also 
counted as background data; the number was 7.5±2.2.
Data analysis and statistics. Three mice with a tumor in the 
left hind leg were used to assess each set of conditions and each 
experiment was repeated three times. Thus, in total, nine mice 
were used for each set of conditions. To examine the differences 
between pairs of values, the Student's t-test was used when vari-
ances of the two groups were assumed to be equal; otherwise the 
Welch's t-test was used. P-values were obtained from two-sided 
tests. P<0.05 was considered to indicate a statistically significant 
difference. The data on cell survival and MN frequencies were 
fitted to the linear-quadratic dose relationship (23).
Results
Toxicity of 10B-carriers and bevacizumab. Table I shows the 
plating efficiencies for the total tumor cell population and the 
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MN frequencies without irradiation for the total and Q cell 
populations. The Q cell population revealed significantly 
higher MN frequencies than the total cell population under 
each set of conditions (P<0.05). The combination with bevaci-
zumab increased the sensitivity of the total cells more than that 
of the Q cells, especially when BPA was employed compared 
with BSH or no 10B-carrier. The difference, however, was not 
significant.
10B concentrations and 10B dose rate during irradiation. 
Table II shows the 10B concentrations and boron dose rates 
in irradiated tumors for each set of conditions. The values are 
averages obtained using the 10B concentrations at the start 
and end points of the irradiation time. The combination with 
bevacizumab increased the concentration, especially when 
BPA was employed compared with BSH. When BPA was 
used as a 10B-carrier, MTH increased the concentration more 
than nicotinamide. By contrast, with BSH as the 10B-carrier, 
nicotinamide increased the concentration more than MTH. 
However, again, these differences were not significant.
Initial tumor response. Fig. 1 shows cell survival curves for 
the total cell population as a function of the absorbed dose 
of neutron beam irradiation with or without a 10B-carrier, in 
combination with nicotinamide or MTH, and in the presence 
or absence of bevacizumab. Fig. 2 shows net MN frequencies 
as a function of irradiated absorbed dose with or without a 
10B-carrier, in combination with nicotinamide or MTH, and 
in the presence or absence of bevacizumab in the total and Q 
tumor cell populations. The net MN frequency was the MN 
frequency in tumors that received irradiation minus the MN 
frequency in tumors that did not. Overall, the net MN frequen-
cies were significantly smaller in Q cells than in the total cell 
population (P<0.05).
Lung metastases from local tumors. To estimate the 
radio-enhancing effect of the 10B-carriers, irradiation with 
BPA and BSH in both the total and Q cell populations was 
compared with neutron beam irradiation only, using the data 
obtained without nicotinamide or MTH shown in Figs. 1 and 
2 (Table III). Both BPA and BSH enhanced the sensitivity 
of the total cell population significantly more than the Q 
Table I. Plating efficiency and micronucleus frequency at 0 Gy.
Variable Without nicotinamide or MTH With nicotinamide With MTH
Plating efficiency (%)
  Without bevacizumab
    Without 10B-carrier 84.4±8.2 81.4±7.3 83.5±8.7
    With BPAc 76.9±7.7 69.9±6.5 73.9±7.3
    With BSHd 81.4±8.3 74.9±6.3 78.9±6.8
  With bevacizumab
    Without 10B-carrier 80.1±8.0 76.3±7.1 78.4±8.3
    With BPA 69.6±7.1 64.8±6.2 68.8±7.0
    With BSH 74.1±7.7 69.8±7.2 73.8±7.1
Micronucleus frequency
  Without bevacizumab
    Total cell population
      Without 10B-carrier 0.050±0.008 0.057±0.006 0.054±0.005
      With BPA 0.063±0.008 0.081±0.008 0.077±0.007
      With BSH 0.059±0.008 0.078±0.009 0.074±0.008
    Quiescent cell population
      Without 10B-carrier 0.077±0.008 0.084±0.009 0.081±0.009
      With BPA 0.091±0.009 0.110±0.011 0.105±0.010
      With BSH 0.095±0.009 0.120±0.011 0.115±0.011
  With bevacizumab
    Total cell population
      Without 10B-carrier 0.058±0.008 0.068±0.007 0.069±0.007
      With BPA 0.071±0.008 0.092±0.009 0.092±0.009
      With BSH 0.067±0.008 0.089±0.009 0.089±0.009
    Quiescent cell population
      Without 10B-carrier 0.083±0.008 0.086±0.009 0.087±0.009
      With BPA 0.097±0.009 0.112±0.011 0.111±0.011
      With BSH 0.101±0.009 0.122±0.011 0.121±0.011
Data are presented as mean ± standard error (n=9). MTH, mild temperature hyperthermia; BPA, l-para-boronophenylalanine-10B; BSH, sodium 
mercaptoundecahydrododecaborate-10B.
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cell population (P<0.05). Furthermore, BPA demonstrated a 
tendency to affect the sensitivity of the total cell population 
more than BSH. By contrast, the sensitivity of the Q cells 
was enhanced more by BSH than BPA. When bevacizumab 
was combined, the sensitivity of the total cells was enhanced 
more than that of the Q cells, especially when BPA was used 
compared with BSH. However, these differences were not 
statistically significant.
Table II. 10B concentration (µg/g=ppm) in tumors and boron dose rate (cGy/h).
Variable Without nicotinamide or MTH With nicotinamide With MTH 
10B concentration (µg/g)
  Without bevacizumab
    BPA 6.9±0.8 7.3±1.0 8.3±1.1
    BSH 7.2±0.9  8.4±1.1 7.9±1.0
  With bevacizumab
    BPA 7.2±0.9 7.4±1.1 8.6±1.2
    BSH 8.0±1.0  8.6±1.2 8.7±1.2
Boron dose rate (cGy/h)
  Without bevacizumab
    BPA 184.2±21.4 194.9±26.7 221.6±29.4
    BSH 192.2±24.0  224.3±29.4 210.9±26.7
  With bevacizumab
    BPA 192.2±24.0 197.6±29.4 229.6±32.0
    BSH 212.7±26.7  229.6±32.0 231.3±32.0
Data are presented as mean ± standard error (n=9). MTH, mild temperature hyperthermia; BPA, L-para-boronophenylalanine-10B; BSH, 
sodium mercaptoundecahydrododecaborate-10B.
Figure 1. Cell survival curves for the total cell population from B16-BL6 
tumors irradiated with reactor neutron beams following the administration 
of a 10B-carrier in combination with nicotinamide treatment, mild tempera-
ture hyperthermia (MTH), or bevacizumab treatment on day 18 following 
tumor cell inoculation. Open and solid symbols represent irradiation without 
and with bevacizumab, respectively. Circle, square, and triangle symbols 
represent irradiation without nicotinamide or MTH, with nicotinamide, and 
with MTH, respectively. Bars represent standard errors (n=9). 10B (-), no 
10B-carrier; BPA, L-para-boronophenylalanine-10B; BSH, sodium mercap-
toundecahydrododecaborate-10B; MTH, mild temperature hyperthermia; BV, 
bevacizumab.





Surviving fraction = 0.3
  Total cell population
    Without bevacizumab 1.7±0.1b,c 1.5±0.1c
    With bevacizumab 2.0±0.15b,d 1.65±0.15d
Net micronucleus frequency = 0.3
  Total cell population 
    Without bevacizumab 2.45±0.15 2.25±0.15 
    With bevacizumab 2.6±0.2 2.35±0.15
  Quiescent cells
    Without bevacizumab 1.5±0.1e 1.8±0.1e 
    With bevacizumab 1.6±0.15 1.85±0.15
Data are presented as mean ± standard error (n=9). aThe ratio of 
the dose of radiation necessary to obtain each end-point without a 
10B-carrier to that needed to obtain each end-point with a 10B-carrier; 
BPA, L-para-boronophenylalanine-10B; BSH, sodium mercaptoun-
decahydrododecaborate-10B; b,c,d,eDifferences between two values 
labeled with the same letter are significant (P<0.05).
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The data in Figs. 1 and 2 were used to estimate the 
radio-enhancing effect of combined treatment with bevaci-
zumab in both the total and Q cell populations (Table IV). With 
or without a 10B-carrier, the sensitivity of the total cell popu-
lation was enhanced when bevacizumab was administered, 
especially when BPA and/or MTH were combined. When 
nicotinamide and MTH were added, sensitivity was more 
suppressed and enhanced, respectively, in the total cells than 
in the Q cells. However, again, the differences were not signifi-
cant.
  A
Figure 2. Dose response curves of the net micronucleus frequency for (A) total and (B) quiescent cell populations from B16-BL6 tumors irradiated with reactor 
neutron beams following the administration of a 10B-carrier in combination with nicotinamide treatment, mild temperature hyperthermia (MTH) or bevaci-
zumab treatment on day 18 following tumor cell inoculation. Open and solid symbols represent irradiation without and with bevacizumab, respectively. Circle, 
square, and triangle symbols represent irradiation without nicotinamide or MTH, with nicotinamide, and with MTH, respectively. Bars represent standard 
errors (n=9). 10B (-), no 10B-carrier; BPA, L-para-boronophenylalanine-10B; BSH, sodium mercaptoundecahydrododecaborate-10B; MTH, mild temperature 
hyperthermia; BV, bevacizumab.
  B
Table IV. Enhancement ratiosa due to combined treatment with bevacizumab.
Variable Without nicotinamide or MTH With nicotinamide With MTH
Surviving fraction = 0.3
  Total cell population
    Without 10B-carrier 1.25±0.1 1.05±0.1 1.3±0.1
    With BPA 1.55±0.2 1.05±0.1 1.7±0.15
    With BSH 1.35±0.1 1.05±0.15 1.35±0.15
Net micronucleus frequency = 0.3
  Total cell population
    Without 10B-carrier 1.1±0.1 1.05±0.1 1.2±0.1
    With BPA 1.2±0.2 1.05±0.1 1.3±0.15
    With BSH 1.15±0.1 1.05±0.1 1.25±0.15
  Quiesent cell population
    Without 10B-carrier 1.05±0.1 1.05±0.1 1.05±0.1
    With BPA 1.05±0.2 1.05±0.1 1.1±0.1
    With BSH 1.1±0.1 1.05±0.1 1.2±0.1
Data are presented as mean ± standard error (n=9). aRatio of the dose of radiation necessary to obtain each end-point without 
bevacizumab to that needed to obtain each end-point with bevacizumab; MTH, mild temperature hyperthermia; BPA, 
L-para-boronophenylalanine-10B; BSH, sodium mercaptoundecahydrododecaborate-10B.
EXPERIMENTAL AND THERAPEUTIC MEDICINE  8:  291-301,  2014 297
The data in Figs. 1 and 2 were also used to estimate the 
radio-enhancing effect of combined treatment with nicotin-
amide or MTH in the total and Q cell populations (Table V). 
With BSH and without a 10B-carrier, the sensitivity of the total 
cell population was more enhanced with nicotinamide than 
with MTH. With BPA, the sensitivity of the total cell popula-
tion was more enhanced with MTH than with nicotinamide. 
By contrast, the sensitivity of the Q cell population was more 
enhanced with MTH than with nicotinamide. Notably, with 
BPA or BSH as the 10B-carrier, MTH enhanced the sensitivity 
of the Q cell populations significantly more than the total 
cell populations (P<0.05). When bevacizumab was used, the 
enhancing effect of nicotinamide was suppressed, especially in 
the total cell population, although not significantly. However, 
the combination with bevacizumab revealed no significant 
effect on the enhancing effect of MTH.
To examine the difference in radio-sensitivity between 
the total and Q cell populations, dose-modifying factors 
were calculated using the data in Figs. 1 and 2 (Table VI). 
Overall, the values obtained were significantly >1.0 (P<0.05). 
Regardless of the 10B-carrier used, the difference in radio-
sensitivity significantly increased (P<0.05), although the 
difference was smaller with BSH than with BPA. The differ-
ence in radio-sensitivity, especially without bevacizumab, was 
increased with nicotinamide and reduced with MTH. However, 
the difference following irradiation without nicotinamide or 
MTH or, in particular, with MTH, was increased with beva-
cizumab. By contrast, the difference following irradiation and 
nicotinamide administration was not significantly altered with 
bevacizumab.
Lung metastases from local tumors. Fig. 3 shows the numbers 
of lung metastases on day 35 following inoculation as a func-
tion of the absorbed dose of neutron beam irradiation with or 
without a 10B-carrier, in combination with nicotinamide or 
MTH, and in the presence or absence of bevacizumab treat-
ment. Without bevacizumab or irradiation, irrespective of a 
10B-carrier, nicotinamide and MTH decreased and increased 
the numbers of macroscopic metastases, respectively. With 
bevacizumab, but under no irradiation, both nicotinamide and 
MTH decreased the number of metastases. With neutron beam 
irradiation, as the absorbed dose increased, the number of 
metastases decreased. Furthermore, the number of metastases 
decreased markedly with a 10B-carrier, especially BPA, than 
without. There was a near-parallel shift in the curves and no 
significant changes in the slopes of the curves for the tumors 
treated without a 10B-carrier or with BPA or BSH. This indi-
cates that no apparent radio-sensitizing or -protecting effect 
was observed with or without bevacizumab, nicotinamide or 
MTH in terms of the numbers of lung metastases. However, 
with irradiation, nicotinamide reduced the numbers of meta-
static nodules from the local tumors treated with the neutron 
beam only, BPA-BNCT, or BSH-BNCT. The combination with 
bevacizumab also reduced the number of metastases from the 
local tumors treated with MTH more than those with nicotin-
amide and without nicotinamide or MTH.
The numbers of lung metastases from local tumors that 
received irradiation under each set of conditions, which 
produced an identical SF of 0.3 as an initial effect (Fig. 1), 
were estimated using the data shown in Fig. 3 (Table VII). 
Overall, BNCT with a 10B-carrier, especially BPA, decreased 
the number of metastases more than neutron beam irradiation 
only. Irrespective of a 10B-carrier, irradiation in combination 
with nicotinamide resulted in a smaller number of metastases 
than any other combination. Further combination with bevaci-
zumab produced further decreased numbers.
Discussion
The cellular distribution of 10B from BSH is considered to be 
mostly dependent on the diffusion of the drug, whereas that 
from BPA is more dependent on the ability of the cells to 
take up 10B (2). Q cell populations have been demonstrated 
Table V. Enhancement ratiosa due to combined treatment with 
nicotinamide or mild temperature hyperthermia.
Variable Nicotinamide MTH
Surviving fraction = 0.3
  Total cell population
    Without bevacizumab
      Without 10B-carrier 1.3±0.15 1.2±0.1
      With BPAc 1.25±0.1 1.4±0.15
      With BSHd 1.5±0.15 1.2±0.1
    With bevacizumab
      Without 10B-carrier 1.2±0.1 1.1±0.1
      With BPA 1.15±0.1 1.35±0.15
      With BSH 1.3±0.15 1.15±0.1
Net micronucleus frequency = 0.3
  Total cell population
    Without bevacizumab
      Without 10B-carrier 1.25±0.1 1.15±0.1
      With BPA 1.15±0.1 1.3±0.1
      With BSH 1.4±0.1 1.2±0.1b
  With bevacizumab
      Without 10B-carrier 1.1±0.1 1.15±0.1
      With BPA 1.1±0.1 1.2±0.1
      With BSH 1.2±0.1 1.15±0.1c
  Quiescent cell population
    Without bevacizumab
      Without 10B-carrier 1.1±0.1 1.2±0.1
      With BPA 1.15±0.1d 1.4±0.1d
      With BSH 1.2±0.1e 1.45±0.15b,e
  With bevacizumab
      Without 10B-carrier 1.05±0.1 1.15±0.1
      With BPA 1.1±0.1f 1.35±0.15f
      With BSH 1.15±0.1g 1.4±0.15c,g
Data are presented as mean ± standard error (n=9). aRatio of the 
dose of radiation necessary to obtain each end-point without com-
bined treatment to that needed to obtain each end-point with the 
combined treatment; MTH, mild temperature hyperthermia; BPA, 
L-para-boronophenylalanine-10B; BSH, sodium mercaptoundecahy-
drododecaborate-10B; b-gDifferences between two values labeled with 
the same letter are significant (P<0.05).
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to have a much larger hypoxic fraction (HF) than total cell 
populations (11). As hypoxic cells are thought to exhibit less 
uptake than aerobic cells (24), it follows that Q cells have a 
lower uptake capacity than the total cell population, and that 
the distribution of 10B from 10B-carriers into Q cells is more 
dependent on the diffusion of the drugs than on the uptake 
ability of the cells.
Perfusion-related acute hypoxia is caused by inadequate 
blood flow in tissues. Tumor microvasculature frequently 
has severe structural and functional abnormalities, such as a 
disorganized vascular network, dilations, an elongated and 
tortuous shape, an incomplete endothelial lining, a lack of 
physiological/pharmacological receptors, an absence of flow 
regulation, and intermittent stasis (25). Perfusion-related O2 
delivery leads to ischemic hypoxia, which is often transient. 
Thus, acute hypoxic areas are distributed throughout the tumor 
depending on these causative factors (8,10,14). Nicotinamide, 
a vitamin B3 analog, prevents these transient fluctuations 
in tumor blood flow that lead to the development of acute 
hypoxia (26). Diffusion-related chronic hypoxia is caused by 
an increase in diffusion distances with tumor expansion. This 
results in an inadequate O2 supply for cells distant (>70 µm) 
from the nutritive blood vessels. Diffusion-related hypoxia 
may also be caused by the deterioration of diffusion ‘geom-
etry’ for example, concurrent versus countercurrent blood flow 
within the tumor microvessel network (10,24). MTH prior 
to irradiation decreased the HF, even when combined with 
nicotinamide administration. By contrast, in a previous study, 
MTH did not decrease the HF when tumor-bearing mice were 
placed in a circulating carbogen (95% O2/5% CO2) chamber 
during irradiation (11). Thus, MTH has been demonstrated to 
increase the tumor response to radiation by improving tumor 
oxygenation through an increase in tumor blood flow (27), 
thereby preferentially overcoming chronic hypoxia rather than 
  A   B
Figure 3. Counted numbers of macroscopic metastases in the lung on day 35 following tumor cell inoculation as a function of the dose of neutron beam 
irradiation (A) without and (B) with bevacizumab treatment following the administration of a 10B-carrier in combination with nicotinamide treatment or mild 
temperature hyperthermia (MTH) on day 18 following tumor cell inoculation. Circle, square, and triangle symbols represent irradiation without nicotinamide 
or MTH, with nicotinamide, and with MTH, respectively. Bars represent standard errors (n=9). 10B (-), no 10B-carrier; BPA, L-para-boronophenylalanine-10B; 
BSH, sodium mercaptoundecahydrododecaborate-10B; MTH, mild temperature hyperthermia.
Table VI. Dose-modifying factors for quiescent cells relative to the total cell populationa (net micronucleus frequency = 0.3).
Variable Without nicotinamide or MTH With nicotinamide With MTH 
Without bevacizumab
  Without 10B-carrier 1.3±0.1 1.45±0.1 1.25±0.1
  With BPA 2.1±0.2 2.35±0.2 1.7±0.15
  With BSH 1.6±0.15 1.75±0.15 1.25±0.1
With bevacizumab
  Without 10B-carrier 1.4±0.1 1.5±0.15 1.4±0.1
  With BPA 2.3±0.2 2.45±0.2 2.1±0.2
  With BSH 1.65±0.15 1.75±0.15 1.45±0.1 
Data are presented as mean ± standard error (n=9). aRatio of the dose of radiation necessary to obtain each end-point in the quiescent cell 
population to that needed to obtain each end-point in the total tumor cell population; MTH, mild temperature hyperthermia; BPA, L-para-
boronophenylalanine-10B; BSH, sodium mercaptoundecahydrododecaborate-10B.
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acute hypoxia. Furthermore, the previous finding that the HFs 
in the total and Q cell populations of B16-BL6 tumors are 
predominantly composed of acute and chronic HFs, respec-
tively needs to be taken into account (12).
The recombinant humanized monoclonal antibody, bevaci-
zumab is composed of the human immunoglobulin G 1 (IgG1) 
framework regions and the antigen-binding regions from the 
murine IgG1 anti-human VEGF monoclonal antibody (28). 
In previous animal experiments, tumor hypoxia decreased 
two days following antiangiogenic treatment, such as VEGF-
blocking therapy, was almost absent by day five, and increased 
again by day eight (7,15). In addition to reducing hypoxia, 
antiangiogenic treatment is considered to be associated with 
the recruitment of pericytes that help to support vessel walls 
to the tumor blood vessel. This stabilizes the broken and 
dilated vasculature that is a common characteristic of tumor 
vessels (29). Pericyte-covered vessels have also been reported 
to decrease in number by day eight following antiangiogenic 
treatment (28). Vascular normalization including the recruit-
ment of pericytes is thought to occur 2-5 days following 
the blocking of VEGF (1,3). During this window, pericyte 
coverage of tumor vessels (11,12) and a reduction in tumor 
vessel permeability and interstitial fluid pressure (30) occur, 
resulting in the normalization of the tumor vessels leading to a 
release from acute hypoxia. The decrease in the HFs induced 
by combining bevacizumab with MTH was more marked than 
that achieved by combining bevacizumab with nicotinamide 
treatment in both the total and Q cell populations.
As shown in Table II, concerning the distribution of 10B in 
the total cell population within tumors, a minor improvement 
was achieved through the chronic hypoxia-releasing treatment 
MTH when BPA, which delivers more 10B to normoxic total 
tumor cells, rather than BSH, was used. By contrast, a small 
improvement was achieved through the acute hypoxia-releasing 
agent nicotinamide or bevacizumab when BSH, which delivers 
more 10B to hypoxic Q cells than BPA, was used. Regardless 
of which 10B-carrier was used, the 10B concentration in tumors 
may be raised by combining the 10B-carrier treatment with a 
treatment that is able to efficiently release the hypoxic areas 
to which the distribution of 10B from each 10B-carrier does not 
readily occur.
The data in table III supports this as when bevacizumab 
was not used, the distribution of 10B in the tumor from BSH 
relied mostly on passive diffusion, whereas that from BPA 
relied on uptake capacity in the tumor by active transport. The 
former resulted in a greater effect on Q cells and the latter, on 
the total tumor cell population. When bevacizumab was used, 
the increase in the enhancement ratio was greater in the total 
cells and with the use of BPA than that in the Q cells and with 
the use of BSH, respectively. This suggests that bevacizumab 
was able to efficiently release the acute hypoxia, resulting in a 
higher uptake of 10B from BPA than from BSH into oxygen-
ated tumor cells originating from a state of acute hypoxia. 
Furthermore, in Table IV, when bevacizumab was used, the 
increase in the enhancement ratio was more marked in the 
total cells, with the use of BPA and with MTH, than in the Q 
cells, with the use of BSH and with nicotinamide, respectively.
Regardless of the presence of bevacizumab, the sensi-
tivity-enhancing effect of nicotinamide and MTH on the total 
cell population (Table V) almost paralleled the changes in the 
10B concentration in tumors shown in Table II. Thus, MTH 
combined with BPA, and nicotinamide combined with BSH 
induced a greater sensitivity-enhancing effect on the total cell 
population. In the Q cell population, MTH induced a signifi-
cantly greater enhancing effect (P<0.05), regardless of which 
10B-carrier was used. When bevacizumab was combined, the 
effect of the nicotinamide combination was reduced as both 
nicotinamide and bevacizumab demonstrated a similar acute 
hypoxia-releasing effect. However, the combination with 
bevacizumab had almost no influence on the effect of MTH 
since the former and the latter exhibited respective acute and 
chronic hypoxia-releasing effects independently. Based on 
these findings, the difference in sensitivity between total and 
Q cell populations increased with nicotinamide or bevaci-
zumab and decreased with MTH (Table VI). Furthermore, the 
fact that the employed reactor neutron beams included not only 
Table VII. Numbers of metastases from the irradiated tumors that received cytotoxic treatment producing a similar initial local 
effecta (surviving fraction = 0.3).
Variable Without nicotinamide or MTH With nicotinamide With MTH
Without bevacizumab
  Without 10B-carrier 17.9 16.6 17.9
    With BPA 15.3 14.5 15.1
    With BSH 15.9 15.2 15.5
With bevacizumab
  Without 10B-carrier 17.4 16.3 16.8
    With BPA 14.5 14.2 14.3
    With BSH 15.6 14.8 15.4
aBased on the data shown in Fig. 4, the estimated numbers of lung metastatic nodules from local tumors that received neu-
tron beam irradiation with or without a 10B-carrier in combination with nicotinamide or mild temperature hyperthermia, which 
produced an identical surviving fraction of 0.3 as an initial effect on Fig. 1; MTH, mild temperature hyperthermia; BPA, 
L-para-boronophenylalanine-10B; BSH, sodium mercaptoundecahydrododecaborate-10B.
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high linear-energy-transfer (LET) neutrons but also low LET 
γ-rays, may have meant that even when a 10B-carrier was not 
used, nicotinamide or bevacizumab and MTH had a marginal 
sensitivity-enhancing effect on the total and Q cell populations, 
respectively. Thus, even without a 10B-carrier, the difference in 
sensitivity between the total and Q cell populations increased 
with nicotinamide or bevacizumab and decreased with MTH 
(Table VI). Since both nicotinamide and bevacizumab demon-
strated a similar acute hypoxia-releasing effect, the difference 
in sensitivity was not changed significantly in combination 
with bevacizumab. By contrast, since bevacizumab and MTH 
induced respective acute and chronic hypoxia-releasing effects 
independently, the difference in sensitivity became clearer in 
combination with bevacizumab than without.
In a previous study BNCT was performed, in combination 
with thalidomide as an antiangiogenic drug, on a short-term 
basis in order to induce a window of vascular normalization 
in the treatment of tumors in a hamster cheek pouch model of 
oral cancer. The blood vessel normalization was not performed 
to increase the total 10B-carrier uptake, but to distribute the 
10B-carriers effectively to a larger proportion of the tumor 
cells by fixing the flawed delivery system (31). In particular, 
pretreatment with thalidomide did not increase the absolute 
boron content in oral tumors but improved boron targeting 
homogeneity. Thus, the effect of tumor blood vessel normal-
ization in BNCT remains to be clarified in future studies.
The presence of Q cells is most likely due, at least in part, 
to hypoxia and the depletion of nutrition as a consequence of 
poor vascular supply (11,30). As a result, Q cells are viable and 
clonogenic, but have ceased dividing. This may promote the 
formation of micronuclei at 0 Gy in Q tumor cells (Table I). 
Q cells have been revealed to have significantly less radiosen-
sitivity than the total cell population (11,30,32). This may also 
be applicable to BNCT as more Q cells survive BNCT than do 
P cells (P<0.05; Fig. 2, Table I). Thus, the control of chronic 
hypoxic Q cells has a significant impact on the outcome of 
BNCT for controlling local tumors, resulting in the superiority 
of BSH as a 10B-carrier in BNCT due to the delivery of more 
10B from BSH in the Q cell population than from BPA. With 
or without a 10B-carrier in the boron neutron capture reaction, 
nicotinamide and bevacizumab enhanced the radiosensitivity 
of the total cell population and MTH enhanced the sensitivity 
of Q cell populations. As a result, the use of nicotinamide or 
bevacizumab led to an increase, while the use of MTH led 
to a reduction, in the difference in radiosensitivity (Table VI). 
Although the use of a 10B-carrier in BNCT, especially BPA, 
significantly increased the difference in radiosensitivity 
between total and Q cell populations (P<0.05), MTH is consid-
ered to be more useful than nicotinamide or bevacizumab in 
terms of local tumor response since it reduces the difference in 
radiosensitivity between radiosensitive total and radioresistant 
Q cell populations. Overall, the use of BSH as a 10B-carrier in 
combination with MTH is considered to be advantageous and 
promising in terms of local tumor response in BNCT.
Hypoxia is believed to enhance metastasis by increasing 
genetic instability (10). Acute, but not chronic, hypoxia has 
been reported to increase the number of macroscopic metas-
tases in mouse lungs (9,10). A previous study reported the 
significance of injecting an acute hypoxia-releasing agent, 
nicotinamide, into tumor-bearing mice as a combined treat-
ment with γ-ray irradiation to repress lung metastasis (12). 
With or without irradiation, nicotinamide and bevacizumab 
appeared to reduce the number of macroscopic metastases 
in the current study (Fig. 4, Table VII). Without irradiation 
or bevacizumab, MTH increased the number of metastases, 
implying that the release from chronic hypoxia is not as 
important in repressing metastasis as the release from acute 
hypoxia. However, hyperthermia is not thought to induce 
metastasis in the clinical setting (33). As the delivered total 
dose increased with irradiation, the number of macroscopic 
lung metastases decreased reflecting the decrease in the 
number of clonogenically viable tumor cells in the primary 
tumor (Fig. 4). The metastasis-repressing effect achieved 
through a reduction in the number of clonogenic tumor cells 
by irradiation is much greater than that achieved by releasing 
tumor cells from acute hypoxia. However, more 10B from BPA 
than from BSH could be distributed into the acute hypoxic 
total tumor cell population, resulting in a greater reduc-
tion in the number of highly clonogenic P tumor cells with 
BPA-BNCT than with BSH-BNCT and with neutron beam 
irradiation only. BPA-BNCT rather than BSH-BNCT has 
certain potential to decrease the number of lung metastases 
and an acute hypoxia-releasing treatment, such as the admin-
istration of nicotinamide or bevacizumab, may be promising 
for reducing the number of lung metastases. Consequently, 
BPA-BNCT in combination with nicotinamide and/or beva-
cizumab treatment may demonstrate a higher potential in 
reducing the number of metastases. Finally, it was revealed 
that control of the chronic hypoxic Q cell population in the 
primary solid tumor has the potential to impact the control of 
local tumors as a whole and that control of the acute hypoxic 
total tumor cell population in the primary solid tumor has the 
potential to impact the control of lung metastases.
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